A Phase II study of AVN 211 in patients with schizophrenia in a condition of incomplete remission receiving stable antipsychotic therapy
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2015
Price : $35 *
At a glance
- Drugs AVN 211 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 16 Jul 2015 Status changed from recruiting to completed as reported in an Avineuro pharmaceuticals media release.
- 16 Jul 2015 Results published in an Avineuro pharmaceuticals media release.
- 25 Jul 2013 New trial record